Finally, the translational relevance of the 100 nM dose remains uncertain due to discrepancies with clinical pharmacokinetics, and the clinical safety at this dose under long-term use still needs to be further evaluated
Differences in brain metabolite levels using MRS have been reported for autistic individuals in multiple brain regions including: the primary sensorimotor cortex SM1(He et al., 2021
Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis
CD40 signaling and plaque instability
Photographer unknown, probably from Karolinska Campus Photo centre
14.2 Obstructive Sleep Apnea Studies in Adults with Obesity Overview of Study 5 and Study 6 The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] 15) in patients with obesity (BMI 30 kg/m2) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52 weeks duration